参考文献/References:
[1].Humbert M,Kovacs G,Hoeper MM,et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J,2023,61(1):2200879.
[2].Bosch L,Lam C,Gong L,et al. Right ventricular dysfunction in left?sided heart failure with preserved versus reduced ejection fraction[J]. Eur J Heart Fail,2017,19(12):1664?1671.
[3].Kolte D,Lakshmanan S,Jankowich MD,et al. Mild pulmonary hypertension is associated with increased mortality:a systematic review and meta-analysis[J]. J Am Heart Assoc,2018,7(18):e009729.
[4].Maron BA,Brittain EL,Hess E,et al. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension:a retrospective cohort study[J]. Lancet Respir Med,2020,8(9):873-884.
[5].Fauvel C,Damy T,Berthelot E,et al. Post-capillary pulmonary hypertension in heart failure:impact of current definition in the PH-HF multicentre study[J].?Eur Heart J,2024,45(35):3274-3288.
[6].Xiao M,Lai D,Yu Y,et al. Pathogenesis of pulmonary hypertension caused by left heart disease[J]. Front Cardiovasc Med,2023,10:1079142.
[7].Assad TR,Hemnes AR,Larkin EK,et al. Clinical and biological insights into combined post- and pre-capillary pulmonary hypertension[J]. J Am Coll Cardiol,2016,68(23):2525-2536.
[8].Obokata M,Kane GC,Reddy YNV,et al. The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction[J]. Eur Heart J,2019,40(45):3707-3717.
[9].Willson C,Watanabe M,Tsuji-Hosokawa A,et al. Pulmonary vascular dysfunction in metabolic syndrome[J]. J Physiol,2019,597(4):1121-1141.
[10].van Duin RWB,Stam K,Cai Z,et al. Transition from post-capillary pulmonary hypertension to combined pre- and post-capillary pulmonary hypertension in swine:a key role for endothelin[J]. J Physiol,2019,597(4):1157-1173.
[11].Rochlani Y,Pothineni NV,Kovelamudi S,et al. Metabolic syndrome:pathophysiology,management,and modulation by natural compounds[J].?Ther Adv Cardiovasc Dis,2017,11(8):215-225.
[12].Robbins IM,Newman JH,Johnson RF, et al. Association of the metabolic syndrome with pulmonary venous hypertension[J]. Chest,2009,136(1):31-36.
[13].Zhou Q,Tang C,Xu X,et al. Serum metabolic profiling implicates mTOR activation and insulin resistance in the development of pulmonary hypertension in a rat model of pressure overload-induced heart failure[J]. Genes Dis,2023,11(5):101097.
[14].King GL,Park K,Li Q. Selective insulin resistance and the development of cardiovascular diseases in diabetes:The 2015 Edwin Bierman Award Lecture[J].?Diabetes,2016,65(6):1462-1471.
[15].Blanco CL,McGill-Vargas LL,Gastaldelli A,et al. Peripheral insulin resistance and impaired insulin signaling contribute to abnormal glucose metabolism in preterm baboons [J].?Endocrinology,2015,156(3):813-823.?
[16].Zuckerbraun BS,Shiva S,Ifedigbo E,et al. Nitrite potently inhibits hypoxic and inflammatory pulmonary arterial hypertension and smooth muscle proliferation via xanthine oxidoreductase-dependent nitric oxide generation[J]. Circulation,2010,121(1):98-109.
[17].Simon MA,Vanderpool RR,Nouraie M,et al. Acute hemodynamic effects of inhaled sodium nitrite in pulmonary hypertension associated with heart failure with preserved ejection fraction[J]. JCI Insight,2016,1(18):e89620.
[18].Tejero J,Shiva S,Gladwin MT. Sources of vascular nitric oxide and reactive oxygen species and their regulation[J]. Physiol Rev,2019,99(1):311-379.
[19].Jia G,DeMarco VG,Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy[J].?Nat Rev Endocrinol,2016,12(3):144-153.
[20].K?nner AC,Brüning JC. Selective insulin and leptin resistance in metabolic disorders [J].?Cell Metab,2012,16(2):144-152.?
[21].Steinberg GR,Hardie DG. New insights into activation and function of the AMPK[J]. Nat Rev Mol Cell Biol,2023,24(4):255-272.
[22].Imai M,Kawakami F,Chiba M,et al. Undaria pinnatifida(wakame) intake ameliorates high-fat diet-induced glucose intolerance via promoting GLUT4 expression and membrane translocation in muscle[J]. J Nutr Metab,2023,2023:9774157.
[23].Hirschey MD,Shimazu T,Jing E,et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome[J]. Mol Cell,2011,44(2):177-190.
[24].Paulin R,Dromparis P,Sutendra G,et al. Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans[J]. Cell Metab,2014,20(5):827-839.
[25].Jing E,Emanuelli B,Hirschey MD,et al. Sirtuin-3(Sirt3) regulates skeletal muscle metabolism and insulin signaling via altered mitochondrial oxidation and reactive oxygen species production[J]. Proc Natl Acad Sci U S A,2011,108(35):14608-14613.
[26].Lai YC,Tabima DM,Dube JJ,et al. SIRT3-AMP-activated protein kinase activation by nitrite and metformin improves hyperglycemia and normalizes pulmonary hypertension associated with heart failure with preserved ejection fraction[J]. Circulation,2016,133(8):717-731.
[27].Wang L,Halliday G,Huot JR,et al. Treatment with treprostinil and metformin normalizes hyperglycemia and improves cardiac function in pulmonary hypertension associated with heart failure with preserved ejection fraction[J]. Arterioscler Thromb Vasc Biol,2020,40(6):1543-1558.
[28].Boden G. Obesity,insulin resistance and free fatty acids[J].?Curr Opin Endocrinol Diabetes Obes,2011,18(2):139-143.
[29].Masenga SK,Kabwe LS,Chakulya M,et al. Mechanisms of oxidative stress in metabolic syndrome[J].?Int J Mol Sci,2023,24(9):7898.
[30].?olak E,Pap D. The role of oxidative stress in the development of obesity and obesity-related metabolic disorders[J]. J Med Biochem,2021,40(1):1-9.
[31].Satoh T,Wang L,Espinosa-Diez C,et al. Metabolic syndrome mediates ROS-miR-193b-NFYA-dependent downregulation of soluble guanylate cyclase and contributes to exercise-induced pulmonary hypertension in heart failure with preserved ejection fraction[J].?Circulation,2021,144(8):615-637.
[32].Zimmer A,Teixeira RB,Constantin RL,et al. The progression of pulmonary arterial hypertension induced by monocrotaline is characterized by lung nitrosative and oxidative stress,and impaired pulmonary artery reactivity[J].?Eur J Pharmacol,2021,891:173699.?
[33].Dolenc J,?ebe?tjen M,Vrtovec B,et al. Pulmonary hypertension in patients with advanced heart failure is associated with increased levels of interleukin-6[J].?Biomarkers,2014,19(5):385-390.
[34].Steiner MK,Syrkina OL,Kolliputi N,et al. Interleukin-6 overexpression induces pulmonary hypertension[J]. Circ Res,2009,104(2):236-244.
[35].Ranchoux B,Nadeau V,Bourgeois A,et al. Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease[J]. Circ Res,2019,125(4):449-466.
[36].Hao B,Xiao Y,Song F,et al. Metformin-induced activation of AMPK inhibits the proliferation and migration of human aortic smooth muscle cells through upregulation of p53 and IFI16[J]. Int J Mol Med,2018,41(3):1365-1376.
[37].Kang S,Kim BR,Kang MH,et al. Anti-metastatic effect of metformin via repression of interleukin 6-induced epithelial-mesenchymal transition in human colon cancer cells[J]. PLoS One,2018,13(10):e0205449.
[38].Engel S?llberg A,Helleberg S,Ahmed S,et al. Plasma tumour necrosis factor-alpha-related proteins in prognosis of heart failure with pulmonary hypertension[J].?ESC Heart Fail,2023,10(6):3582-3591.?
[39].Shao Z,Wang Z,Shrestha K,et al. Pulmonary hypertension associated with advanced systolic heart failure:dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1[J]. J Am Coll Cardiol,2012,59(13):1150-1158.
相似文献/References:
[1]陈炜,许贞蓉.表观遗传学与代谢性心血管疾病的研究进展[J].心血管病学进展,2019,(6):902.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.016]
CHEN Wei,XU Zhenrong.Epigenetics and Cardiometabolic Disease[J].Advances in Cardiovascular Diseases,2019,(1):902.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.016]
[2]占小锋 张长磊 李刚.β肾上腺素受体阻滞剂对甘油三酯代谢的影响及其作用机制的阐述[J].心血管病学进展,2019,(9):1298.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.029]
ZHAN Xiaofeng,ZHANG Changlei,LI Gang.Effect of -adrenergic Receptor Blockers on Triglyceride Metabolism and Mechanism[J].Advances in Cardiovascular Diseases,2019,(1):1298.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.029]
[3]李莎 熊峰.胰岛素抵抗与心血管疾病研究进展[J].心血管病学进展,2019,(9):1307.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.032]
Li ShaXiong Feng.Insulin Resistance and Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(1):1307.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.032]
[4]位晨晨,钟明.糖尿病心肌病的发病机制[J].心血管病学进展,2020,(2):135.[doi:10.16806/j.cnki.issn.1004-3934.20.02.009]
WEI Chenchen,ZHONG Ming.Pathogenesis of Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(1):135.[doi:10.16806/j.cnki.issn.1004-3934.20.02.009]
[5]任蕾 夏芳芳 戴红艳.血管生成素样蛋白6在心血管病方面的研究进展[J].心血管病学进展,2020,(4):388.[doi:10.16806/j.cnki.issn.1004-3934.20.04.015]
REN Lei,XIA FangFang,DAI HongYan.Relationship Between ANGPTL6 and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(1):388.[doi:10.16806/j.cnki.issn.1004-3934.20.04.015]
[6]杨晓倩 秦莉 张艺文 童兰 汪汉.糖皮质激素与心血管疾病[J].心血管病学进展,2020,(4):404.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.019]
YANG Xiaoqian,QIN Li,ZHANG Yiwen,et al.Glucocorticoid and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(1):404.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.019]
[7]樊德慧 金娟 韩宇博 田苗 刘莉.利钠肽与代谢综合征的研究进展[J].心血管病学进展,2020,(10):1074.[doi:10.16806/j.cnki.issn.1004-3934.20.10.018]
FAN Dehui,JIN Juan,HAN Yubo,et al.Research Progress of Natriuretic Peptide and Metabolic Syndrome[J].Advances in Cardiovascular Diseases,2020,(1):1074.[doi:10.16806/j.cnki.issn.1004-3934.20.10.018]
[8]廖丽萍 周跟东 张晓红.血清甘油三酯葡萄糖乘积指数与代谢性疾病的研究进展[J].心血管病学进展,2020,(11):1189.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[9]王晓琪 苏冠华.高尿酸血症和心力衰竭的病理生理机制、治疗和预后价值[J].心血管病学进展,2021,(9):780.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
WANG Xiaoqi,SU Guanhua.Pathophysiological Mechanism, Treatment and Prognostic Value of Hyperuricemia and Heart Failure[J].Advances in Cardiovascular Diseases,2021,(1):780.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[10]蔡薇 杨堰焯 刘昊凌.甘油三酯葡萄糖乘积指数与糖尿病血管病变的研究进展[J].心血管病学进展,2022,(3):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
CAI Wei,YANG Yanzhuo,LIU Haoling.Triglyceride-Glucose Index and Diabetic Vascular Disease[J].Advances in Cardiovascular Diseases,2022,(1):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]